Optimizing measurement of EGFR mutation status in NSCLC

被引：0
|
作者：
Nicolson, M.
Clark, C.
Bell, C.
Osborne, A.
Tracey, J.
Petty, R. D.
Kerr, K. M.
机构：
[1] Aberdeen Royal Infirm, Aberdeen, Scotland
[2] Univ Aberdeen, Aberdeen, Scotland
[3] Univ Aberdeen, Aberdeen Royal Infirm, Aberdeen, Scotland
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2010年 / 28卷 / 15期
关键词：
D O I：
10.1200/jco.2010.28.15_suppl.e18120
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e18120
引用
收藏
页数：1
相关论文
共 50 条
  • [1] In advanced NSCLC EGFR Mutation Status test
    Schuette, Wolfgang
    [J]. ONKOLOGIE, 2012, 35 (06): : 393 - 393
  • [2] EGFR mutation in NSCLC in Pakistan
    Ahmed, Z. A.
    Moatter, T.
    Pervez, S.
    Khan, W.
    [J]. ANNALS OF ONCOLOGY, 2016, 27
  • [3] Can CT radiomic analysis in NSCLC predict histology and EGFR mutation status?
    Digumarthy, Subba R.
    Padole, Atul M.
    Lo Gullo, Roberto
    Sequist, Lecia V.
    Kalra, Mannudeep K.
    [J]. MEDICINE, 2019, 98 (01) : E13963
  • [4] Evaluation of concurrent chemoradiotherapy for locally advanced NSCLC according to EGFR mutation status
    Ishihara, Mikiko
    Igawa, Satoshi
    Sasaki, Jiichiro
    Otani, Sakiko
    Fukui, Tomoya
    Ryuge, Shinichiro
    Katono, Ken
    Hiyoshi, Yasuhiro
    Kasajima, Masashi
    Mitsufuji, Hisashi
    Kubota, Masaru
    Yokoba, Masanori
    Katagiri, Masato
    Sekiguchi, Akane
    Soda, Itaru
    Ishiyama, Hiromichi
    Hayakawa, Kazushige
    Masuda, Noriyuki
    [J]. ONCOLOGY LETTERS, 2017, 14 (01) : 885 - 890
  • [5] Optimizing Patient Outcomes Through Sequential EGFR TKI Treatment in Asian Patients With EGFR Mutation-Positive NSCLC
    Liu, Rong
    Zhou, Jianying
    Ling, Xia
    [J]. CLINICAL MEDICINE INSIGHTS-ONCOLOGY, 2022, 16
  • [6] TREATMENT OF NSCLC PATIENTS WITH EGFR MUTATION
    Yang, J. C. -H.
    [J]. ANNALS OF ONCOLOGY, 2012, 23 : 29 - 29
  • [7] Optimizing Patient Outcomes Through Sequential EGFR TKI Treatment in Asian Patients With EGFR Mutation-Positive NSCLC
    Liu, Rong
    Zhou, Jianying
    Ling, Xia
    [J]. CLINICAL MEDICINE INSIGHTS-ONCOLOGY, 2022, 16
  • [8] Optimizing outcomes in EGFR mutation-positive NSCLC: which tyrosine kinase inhibitor and when?
    Girard, Nicolas
    [J]. FUTURE ONCOLOGY, 2018, 14 (11) : 1117 - 1132
  • [9] EGFR Mutation Testing and First Line Treatment of Patients With Advanced NSCLC and Positive EGFR Mutation Status - Results From a German Registry
    Eberhardt, W.
    Thomas, M.
    von der Schulenburg, J. M. Graf
    Dietel, M.
    Schirmacher, P.
    Gutendorf, B.
    Zirrgiebel, U.
    Schuette, W.
    [J]. EUROPEAN JOURNAL OF CANCER, 2011, 47 : S636 - S636
  • [10] Assessment of EGFR mutation status in matched plasma and tumor tissue of NSCLC patients.
    Feng, Qin
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
12345